19. Management strategies refined:
The emerging role of thiazolidinediones in type 2 diabetes

Sunday, September 17, 2000
14:00-17:30

Session I:
14:00-14:05 Chairperson's introduction
14:05-14:40 Discovery of the thiazolidinedione class and its distinct features
Hitoshi Ikeda, Japan
14:40-15:15 Insulin resistance: How important is it to treat?
Gerald M. Reaven, USA
15:15-15:50 Type 2 diabetes: Management targets and goals
David R. Matthews, UK
15:50-16:10 Coffee Break (auditorium)
Session 2:
16:10-16:45 Clinical experience with pioglitazone
Robert S. Sherwin, USA
16:45-17:30 Clinical case presentation
Burkhard G?ke, Switzerland
Panel discussion: Massimo Massi-Benedetti, Italy; David R. Matthews, UK; Hitoshi Ikeda, Japan; Gerald M. Reaven, USA; Robert S. Sherwin, USA; Burkhard G?ke, Switzerland


Laromme Hotel


Massimo Massi-Benedetti, Italy
David R. Matthews, UK


Takeda Chemical Industries, Ltd., Japan

FOR GENERAL, REGISTRATION AND ABSTRACT ENQUIRIES
Miwa Yoshitake, Project Coordinator
Biomedis International Takeda In-House Office
c/o Pharmaceutical International Division
Takeda Chemical Industries, Ltd.
4-1-1 Doshomachi, Chuo-ku, Osaka 540-8645, JAPAN
Tel: +81 6 6221 3045
Fax: +81 6 6221 3046
E-mail: miwako-y@biomedis.co.jp